Prostate Cancer Recurrence Risk Dropped in Phase 3 Trial
A novel immunotherapy approach combined with radiation reduced recurrence or death in trial participants.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Do you believe positive clinical trial results make now a good time to invest in biotech?
A Phase 3 study found that the investigational treatment CAN-2409 reduced the risk of prostate cancer recurrence or death by 41 percent when used alongside radiation therapy. This study provides new data on how targeted immune system activation may improve patient outcomes.
Why it matters
This development represents a potential new treatment path for prostate cancer patients seeking to lower the risk of disease progression. By enhancing the immune response against tumor cells, the therapy aims to build upon the standard efficacy of radiation treatment.
This Phase 3 trial result demonstrated that CAN-2409 combined with radiation therapy reduced the risk of recurrence or death by 41% compared to placebo plus radiation. AI-based analysis confirmed increased lymphocyte presence within tumors that persisted for more than two years.
The players
Candel Therapeutics
A clinical-stage biotechnology company focused on developing viral immunotherapies for cancer treatment.
FDA
The United States federal agency responsible for regulating biological products and medical therapies.
The details
CAN-2409 works by being injected directly into tumors to trigger the death of cancer cells. This process activates the patient's own immune system to recognize and attack the remaining abnormal cells. The treatment is designed to create a more potent immune environment within the tumor, as evidenced by the sustained presence of lymphocytes noted in the study.
Timeline
June 2026: Candel Therapeutics held $201.6 million in cash.
September 30, 2026: The company unveiled new Phase 3 trial data.
Q4 2026: Candel plans to submit a Biologics License Application to the FDA.
Q1 2028: Projected cash reserves for operations end.
Health Landscape
This development marks a progress point in the broader push toward integrating immunotherapy with traditional radiation treatments. It follows the ongoing Phase 3 trial for CAN-2409 in patients with advanced non-small cell lung cancer, signaling the drug's evolving role in oncology pipelines.
Patients currently managing prostate cancer should discuss these emerging immunotherapy developments with their oncologist to understand if such trials or future therapies may eventually align with their care plan. It is essential to focus on established treatment protocols while monitoring progress on new therapies undergoing FDA review.
The takeaway
The study suggests that targeting tumor cells with a combination of injection therapy and radiation may significantly lower the risk of cancer returning. Patients should continue working with their physicians to track updates on the Biologics License Application scheduled for late 2026.
Further reading
For more information on evolving treatment standards, visit Cancer.
Live Poll
Do you believe positive clinical trial results make now a good time to invest in biotech?
